Monte Rosa Therapeutics Inc (GLUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has a cash flow conversion efficiency ratio of -0.072x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.37 Million) by net assets ($521.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Monte Rosa Therapeutics Inc to measure how much of total assets are equity-financed.
Monte Rosa Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Monte Rosa Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Monte Rosa Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Monte Rosa Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Zhongke Electric
SHE:300035
|
-0.089x |
|
Alrov Properties & Lodgings Ltd
TA:ALRPR
|
0.002x |
|
Adapthealth Corp
NASDAQ:AHCO
|
0.099x |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
0.759x |
|
Befesa SA
XETRA:BFSA
|
0.037x |
|
China Merchants Property Operation & Service Co Ltd
SHE:001914
|
0.256x |
|
Global Ship Lease Inc
NYSE:GSL
|
0.043x |
|
Golden Ocean Group Limited
F:KT31
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Monte Rosa Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Monte Rosa Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Monte Rosa Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $233.06 Million | $-22.80 Million | -0.098x | -151.93% |
| 2024-12-31 | $222.94 Million | $42.00 Million | 0.188x | +177.09% |
| 2023-12-31 | $179.25 Million | $-43.80 Million | -0.244x | +28.27% |
| 2022-12-31 | $271.41 Million | $-92.47 Million | -0.341x | -99.44% |
| 2021-12-31 | $347.51 Million | $-59.36 Million | -0.171x | -136.11% |
| 2020-12-31 | $-48.73 Million | $-23.05 Million | 0.473x | -6.90% |
| 2019-12-31 | $-12.15 Million | $-6.17 Million | 0.508x | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more